Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR ) 37.63 -0.50 (-1.31%) Streaming Delayed Price Updated: 2:27 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Structure Therapeutics Inc. - American Depositary Shares Structure Therapeutics Appoints Angus C. Russell to Board of Directors August 27, 2024 Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Participation in Upcoming Investor Conferences August 26, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights August 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug July 09, 2024 Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been Via MarketBeat Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? July 03, 2024 Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases Via MarketBeat Exposures Product Safety Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes July 02, 2024 Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy Via MarketBeat Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares June 07, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering June 05, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants June 03, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 June 03, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights May 09, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference March 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights March 08, 2024 From Structure Therapeutics Inc. Via GlobeNewswire IPO watch 2024: Which new stocks will hit the market? January 08, 2024 Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. Via MarketBeat Topics Initial Public Offering Exposures Securities Market Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study December 18, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights November 14, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders October 19, 2023 EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia Structure Therapeutics Announces $300 Million Private Placement Equity Financing September 29, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update September 29, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights August 10, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors August 03, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions June 07, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics to Present at Jefferies Healthcare Conference May 31, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity May 25, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference May 18, 2023 Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights May 11, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights March 30, 2023 From Structure Therapeutics Inc. Via GlobeNewswire There's a Lot to Love About Mineralys' Valentine's Day IPO February 13, 2023 MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million Via MarketBeat Topics Initial Public Offering Exposures Securities Market Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares February 07, 2023 From Structure Therapeutics Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.